No Data
No Data
Sunshine Guojian Pharmaceutical (Shanghai)'s H1 Attributable Profit Jumps 37%
Sunshine Guojian Pharmaceutical: Half-year report for the year 2024.
Sunshine Guojian Pharmaceutical: Summary of Half-Year Report in 2024.
Guojian Pharmaceutical Completes Psoriasis Drug Clinical Trial
Sunshine Guojian Pharmaceutical's recombined anti-IL-4Rα humanized monoclonal antibody injection (611) for the treatment of chronic sinusitis with nasal polyps Phase II clinical study achieved the main endpoint.
Shanghai, August 9, 2024 / PRNewswire / - Today, Sunshine Guojian Pharmaceutical (Stock Code: 688336.SH) announced that the Phase II clinical study of the company's independently developed recombinant humanized anti-IL-4Rα monoclonal antibody injection (Research and development code: 611) for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) has achieved its primary endpoint. The study included 100 CRSwNP subjects who were randomly assigned to the experimental drug Group A (611 300mg Q2W), experimental drug Group B (611 450mg Q4W), and safety control group at a ratio of 1: 1: 1.
Sunshine Guojian Pharmaceutical (688336.SH): SSGJ-608 has successfully achieved all efficacy endpoints in Phase III clinical trials for psoriasis, accelerating the listing process.
Sunshine Guojian Pharmaceutical (688336.SH) announced a reorganization of the injection of anti-IL-17A humanized monoclonal antibodies (...
No Data